CDRE vs ENOV: stock comparison and AI forecast
Cadre Holdings, Inc. (CDRE) and Enovis Corp (ENOV) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CDRE Cadre Holdings, Inc.
- Price
- $32.27 +7.9% · 6M
- Market Cap
- $1.38B
- P/E Ratio
- 28.8x
- Size
- small-cap
- AI Forecast
ENOV Enovis Corp
- Price
- $28.62 +5.0% · 6M
- Market Cap
- $1.65B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ENOV is 1.2 times larger than CDRE by market capitalization ($1.65B against $1.38B).
- Over the last six months CDRE returned +7.9% and ENOV +5.0%.
- CDRE turns 5.6% of its revenue into net income, against -22.9% for ENOV.
- CDRE carries 1.52 times debt per unit of equity, against 1.50 times for ENOV.
- CDRE yields 1.21% in dividends; ENOV pays none.
- Both companies share the SEC industry classification Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CDRE | ENOV |
|---|---|---|
| Market Cap | $1.38B | $1.65B |
| P/E Ratio | 28.81x | – |
| P/B Ratio | 3.77x | 1.11x |
| Dividend Yield | 1.21% | – |
| EPS | $1.12 | $-10.06 |
| Book Value/Share | $8.57 | $25.89 |
| Revenue/Share | $17.11 | $39.99 |
| FCF/Share | $1.78 | $1.21 |
Profitability & Margins
| Metric | CDRE | ENOV |
|---|---|---|
| ROE | 11.2% | -35.3% |
| ROA | 4.5% | -14.1% |
| ROIC | 10.2% | -15.1% |
| Gross Margin | 42.0% | 61.3% |
| Operating Margin | 10.8% | -20.6% |
| Net Margin | 5.6% | -22.9% |
| EBT Margin | 8.4% | -21.8% |
| Tax Rate | 33.0% | -5.0% |
Financial Health
| Metric | CDRE | ENOV |
|---|---|---|
| Current Ratio | 2.35x | 2.15x |
| Quick Ratio | 1.51x | 1.08x |
| D/E Ratio | 1.52x | 1.50x |
| Financial Leverage | 2.52x | 2.50x |
| Interest Coverage | 4.9x | 0.4x |
| Working Capital | $205M | $668M |
Cash Flow
| Metric | CDRE | ENOV |
|---|---|---|
| Operating Cash Flow | $89M | $259M |
| Free Cash Flow | $76M | $70M |
| Capital Spending | -$12M | -$189M |
| OCF Growth YoY | 34.3% | 19.3% |
| FCF Growth YoY | 24.6% | 205.6% |
| FCF/Sales | 10.4% | 3.0% |
| CapEx/Sales | 1.7% | 8.2% |
Operational Efficiency
| Metric | CDRE | ENOV |
|---|---|---|
| Asset Turnover | 0.79x | 0.62x |
| Receivables Turnover | 5.8x | 5.4x |
| Inventory Turnover | 3.4x | 1.4x |
| Fixed Assets Turnover | 5.9x | 4.4x |
| Days Sales Outstanding | 63 days | 68 days |
| Days Inventory | 109 days | 254 days |
| Payables Period | 30 days | 82 days |
| Cash Conversion Cycle | 142 days | 239 days |
Income Statement
| Metric | CDRE | ENOV |
|---|---|---|
| Total Revenue | $733M | $2.31B |
| Operating Income | $79M | -$475M |
| Net Income | $41M | -$527M |
| R&D Expense | – | $126M |
| SG&A Expense | $222M | $1.08B |
| Cost of Goods Sold | $425M | $892M |
Dividend & Shareholder Information
| Metric | CDRE | ENOV |
|---|---|---|
| Dividends Per Share | $0.39 | – |
| Payout Ratio | 34.8% | – |
| Shares Outstanding | 43M | 58M |
| Net Income Growth | -9.4% | – |
| EPS Growth | 3.7% | – |
CDRE vs ENOV: stock comparison and AI forecast
Which is bigger, CDRE or ENOV?
ENOV is 1.2 times larger than CDRE by market capitalization ($1.65B against $1.38B).
Which stock performed better over the last six months, CDRE or ENOV?
Over the last six months CDRE returned +7.9% and ENOV +5.0%.
Which one does Intratio's AI model rank higher, CDRE or ENOV?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.